Novartis on CAR T division: ‘Reintegrated but still committed’
The cell and gene therapy unit back will be reintegrated into the main business Novartis says, denying it has turned its back on CAR T therapies.
Archives for September 1, 2016
Streamlined Protein A production will lower costs for mAb makers, Purolite
Welsh chromatography resin maker Purolite says it aims to capture 30% of the Protein A market through its 100,000L facility on track to open next year.
Vibalogics expands German fill/finish site on back of clinical demand
German CDMO Vibalogics has upped its capabilities 300% citing a lack of worldwide capacity for biologics fill and finish.